TALOS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO TEST THE VASCULAR AND NEUROPROTECTIVE EFFECTS OF CITALOPRAM IN PATIENTS WITH ACUTE ISCHEMIC STROKE
World Stroke Academy. Kraglund K. 05/16/17; 183379 Disclosure(s): Honoraria from BMS and Pfizer
Kristian Lundsgaard Kraglund
Kristian Lundsgaard Kraglund
All contributions
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

You may also access WSO content "anytime, anywhere" with the FREE World Stroke Academy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions
What's new

ESO-WSO 2020 | Joint Stroke Conference - Vienna, 12-15 May 2020

World Stroke Day 2019: When it comes to stroke, #DontBeTheOne. 

About Us
The World Stroke Academy is a core educational activity of the World Stroke Organization and provides high-quality stroke education to healthcare professionals.
2020 ©

World Stroke Organizaton

USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies